Query author contributions in Reactome
Reactome depends on collaboration between our curation team and outside experts to assemble and peer-review its pathway modules. The integration of ORCID within Reactome enables us to meet a key challenge with authoring, curating and reviewing biological information by incentivizing and crediting the external experts that contribute their expertise and time to the Reactome curation process. More information is available at ORCID and Reactome.
If you have an ORCID ID that is not listed on this page, please forward this information to us and we will update your Reactome pathway records.
Details on Person Factor Xa (aka Factor X heavy chain), a cleavage product of ...
| Class:Id | Summation:9015120 |
|---|---|
| _displayName | Factor Xa (aka Factor X heavy chain), a cleavage product of ... |
| _timestamp | 2018-03-23 10:09:13 |
| created | [InstanceEdit:9015121] Jassal, Bijay, 2017-08-08 |
| literatureReference | [LiteratureReference:9015060] The new oral anticoagulants for the treatment of venous thromboembolism: a new paradigm shift in antithrombotic therapy [LiteratureReference:9015186] Pharmacology of anticoagulants used in the treatment of venous thromboembolism |
| modified | [InstanceEdit:9015185] Jassal, Bijay, 2017-08-09 [InstanceEdit:9015703] Jassal, Bijay, 2017-08-11 [InstanceEdit:9015707] Jassal, Bijay, 2017-08-11 [InstanceEdit:9017155] Jassal, Bijay, 2017-08-17 [InstanceEdit:9026992] Jassal, Bijay, 2017-10-25 [InstanceEdit:9038796] Jassal, Bijay, 2018-03-14 [InstanceEdit:9603675] Jassal, Bijay, 2018-03-23 |
| text | Factor Xa (aka Factor X heavy chain), a cleavage product of coagulation factor X (F10), is a vitamin K-dependent glycoprotein able to convert prothrombin to thrombin during the blood clotting process. Factor Xa is a target for direct oral anticoagulant (DOAC) drugs that are direct factor Xa inhibitors (the so-called 'xabans') which are used in the treatment and prevention of thromboembolic disorders (Galanis et al. 2014, Nutescu et al. 2016). Rivaroxaban (brand name Xarelto) binds to and inhibits both free factor Xa and factor Xa bound in the prothrombinase complex (Va:Xa) (Roehrig et al. 2005). Rivaroxaban was the first medically approved drug of this class (Abrams & Emerson 2009, Misselwitz et al. 2011). Other 'xabans' such as apixaban (Bhanwra & Ahluwalia 2014), edoxaban (Minor et al. 2015), eribaxaban (Bondarenko et al. 2013) and betrixaban (Zhang et al. 2009) share a similar mechanism of action to rivaroxaban (Nutescu et al. 2016). |
| (summation) | [Reaction:9015122] Factor Xa inhibitors bind Va:Xa [Homo sapiens] |
| [Change default viewing format] | |
No pathways have been reviewed or authored by Factor Xa (aka Factor X heavy chain), a cleavage product of ... (9015120)
